Dose-Related Seroreversal in Syphilis

Durst, Robert D.

doi:10.1001/archderm.1973.01620260013003

Cited by 13 publications

(2 citation statements)

References 6 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…One might speculate that there would have been a better outcome with the application of an additional depot preparation instead of an oral regimen, a concept already proposed in early treatment studies. 9–11 Compared with these data, we observed significantly lower failure rates, regardless of the treatment regimen. In our study, contrary to our expectations, the extended treatment was not superior to standard therapy; in fact it was even inferior.…”

Section: Discussionsupporting

confidence: 40%

“…A number of studies observed seroreversion rates of less than 50% after 1 year; 8 as a consequence, some authors have recommended an extended treatment regimen. 9,10 If non-treponemal antibodies remain serofast at low titres following treatment, is this an indication for re-treatment or a sign of failure? The evaluation of the decline in the non-treponemal test titre within a defined time period offers a better assessment of treatment response.…”

Section: Discussionmentioning

confidence: 99%

See 1 more Smart Citation

Enhanced therapy for primary and secondary syphilis: a longitudinal retrospective analysis of cure rates and associated factors

et al. 2013

View full text Add to dashboard Cite

For the treatment of early infectious syphilis, enhanced therapy with three dosages of benzathine penicillin G has been under consideration, particularly in the human immunodeficiency virus type 1 infected population (HIV-1). The serological outcome of 249 patients with primary and secondary syphilis treated with standard or enhanced therapy was analyzed retrospectively; 98% (139/142) achieved serological cure with a single dosage and 92% with enhanced therapy (P=0.033). In HIV-1 infected individuals, cure rates were 88% after a single dosage compared to 97% after three dosages (P=0.18). A fourfold decrease of Venereal Disease Research Laboratory (VDRL) titres was achieved within a median of 102 days after treatment initiation (SD=2; 95% CI=98-106). Patients aged over 40 years were 5.5 times (OR=5.52; 95% CI=1.43-21.32; P=0.013) and patients with low baseline VDRL titres (≤ 1:32) were 4 times (OR=4.25; 95% CI=1.21-14.87; P=0.024) more likely to experience serological failure.

show abstract

Section: Discussionsupporting

confidence: 40%